|
🐜
|
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
24 auth.
A. Oza,
A. Cook,
J. Pfisterer,
A. Embleton,
J. Ledermann,
E. Pujade-Lauraine,
G. Kristensen,
M. Carey,
P. Beale,
A. Cervantes,
...
T. Park-Simon,
G. Rustin,
F. Joly,
M. Mirza,
M. Plante,
M. Quinn,
A. Poveda,
G. Jayson,
D. Stark,
A. Swart,
L. Farrelly,
R. Kaplan,
M. Parmar,
T. Perren
|
9 |
2015 |
9
🐜
|
|
🐜
|
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
19 auth.
J. Ledermann,
A. Embleton,
F. Raja,
T. Perren,
G. Jayson,
G. Rustin,
S. Kaye,
H. Hirte,
E. Eisenhauer,
M. Vaughan,
...
M. Friedlander,
A. González-Martín,
D. Stark,
E. Clark,
L. Farrelly,
A. Swart,
A. Cook,
R. Kaplan,
M. Parmar
|
7 |
2016 |
7
🐜
|
|
🐜
|
Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial
10 auth.
J. Ledermann,
T. Perren,
F. Raja,
A. Embleton,
G. Rustin,
G. Jayson,
...
S. Kaye,
A. Swart,
M. Vaughan,
H. Hirte
|
6 |
2013 |
6
🐜
|
|
🐜
|
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
27 auth.
S. Kommoss,
B. Winterhoff,
A. Oberg,
G. Konecny,
Chen Wang,
S. Riska,
Jian-Bing Fan,
M. Maurer,
Craig S. April,
V. Shridhar,
F. Kommoss,
A. du Bois,
F. Hilpert,
S. Mahner,
K. Baumann,
...
W. Schroeder,
A. Burges,
U. Canzler,
J. Chien,
A. Embleton,
M. Parmar,
R. Kaplan,
T. Perren,
L. Hartmann,
E. Goode,
S. Dowdy,
J. Pfisterer
|
6 |
2017 |
6
🐜
|
|
🐜
|
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients
7 auth.
A. R. Halvorsen,
Gunnar B. Kristensen,
A. Embleton,
C. Adusei,
M. Barretina-Ginesta,
P. Beale,
...
Å. Helland
|
5 |
2017 |
5
🐜
|
|
🐜
|
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
15 auth.
A. González Martín,
A. Oza,
A. Embleton,
J. Pfisterer,
J. Ledermann,
E. Pujade-Lauraine,
G. Kristensen,
Monique A. Bertrand,
P. Beale,
A. Cervantes,
...
E. Kent,
R. Kaplan,
M. Parmar,
N. Scotto,
T. Perren
|
5 |
2019 |
5
🐜
|
|
🐜
|
Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.
20 auth.
B. Winterhoff,
S. Kommoss,
A. Oberg,
Chen Wang,
S. Riska,
G. Konecny,
Jian-Bing Fan,
V. Shridhar,
E. Goode,
F. Kommoss,
...
A. Bois,
F. Hilpert,
J. Chien,
A. Embleton,
M. Parmar,
R. Kaplan,
T. Perren,
L. Hartmann,
J. Pfisterer,
S. Dowdy
|
5 |
2014 |
5
🐜
|
|
🐬
|
The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
S. Hinde,
D. Epstein,
A. Cook,
A. Embleton,
T. Perren,
M. Sculpher
|
4 |
2016 |
4
🐬
|
|
🐜
|
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
11 auth.
D. Stark,
A. Cook,
Julia M. Brown,
M. Brundage,
A. Embleton,
R. Kaplan,
...
F. Raja,
A. Swart,
G. Velikova,
W. Qian,
J. Ledermann
|
4 |
2017 |
4
🐜
|
|
🐜
|
Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer.
18 auth.
J. Ledermann,
A. Embleton,
T. Perren,
G. Jayson,
G. Rustin,
S. Kaye,
H. Hirte,
A. Oza,
M. Vaughan,
M. Friedlander,
...
Antonio González Martín,
E. Clark,
B. Popoola,
L. Farrelly,
A. Swart,
A. Cook,
R. Kaplan,
M. Parmar
|
4 |
2017 |
4
🐜
|
